Single Source for the Continuation of Cure Glomerulonephropathy (CureGN) Data Coordinating Center (U24 Clinical Trial Not Allowed) | RFA DK 22 513

Opportunity Information: Apply for RFA DK 22 513

This grant opportunity, RFA-DK-22-513, is a National Institutes of Health (NIH) funding announcement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that is explicitly described as a single-source, non-competitive action. In practical terms, that means NIH is not seeking a broad field of competing applications. Instead, NIDDK is stating its intent to make one cooperative agreement award, and the intended recipient is the University of Michigan. The overarching aim is continuity: keeping the Cure Glomerulonephropathy (CureGN) Network moving forward by maintaining the infrastructure and leadership provided by its Data Coordinating Center (DCC). The notice also makes clear that this is a U24 mechanism and that a clinical trial is not allowed under this award, which aligns with CureGN being structured as an observational cohort effort rather than an interventional trial.

CureGN itself is described as a multicenter observational cohort study focused on people with glomerular diseases. The network’s purpose is to generate high-quality, real-world clinical and research data that can translate into better understanding of disease progression and, ultimately, improved care for patients across a range of glomerular conditions. Because observational cohort studies depend on consistency over time, stable operations, standardized data capture, and long-term follow-up, the DCC is positioned as a central hub that keeps the project scientifically coherent and operationally reliable across multiple clinical sites.

The Data Coordinating Center’s role is framed as both leadership and execution across the core functions that make a large network study work. That includes study organization and governance support, contribution to study design and ongoing implementation details, and overall operational management across the network. It also includes the technical backbone: data management systems, quality control, and analytic support so that the network’s information is clean, harmonized, secure, and usable for planned analyses. In addition, the DCC is responsible for biosample management, which typically involves coordinating how specimens are collected, processed, tracked, stored, and linked to clinical data in ways that preserve scientific value and protect participant confidentiality. Taken together, these responsibilities reflect why a DCC is often treated as essential shared infrastructure rather than simply another participating site.

The announcement distinguishes the DCC from the CureGN Participating Clinical Centers (PCCs). While this particular award is aimed at continuing the DCC, the PCCs are expected to continue following previously enrolled participants under a separate notice of funding opportunity. That division is important: it signals that ongoing participant follow-up and site-based clinical activities are being maintained through different funding streams, while this single-source U24 is focused on sustaining the centralized coordination, data systems, and cross-site standardization needed to keep the entire network functioning as one integrated study.

From an administrative standpoint, the funding instrument is a cooperative agreement, not a standard grant. Cooperative agreements generally involve substantial NIH programmatic involvement, meaning NIDDK is likely to remain actively engaged in oversight, coordination, and major scientific or operational decisions as the work continues. The activity category is health-related (with listings indicating Food and Nutrition, Health) and the CFDA number provided is 93.847, which corresponds to NIDDK-related assistance programs.

Key logistical details in the source summary include an original closing date of October 19, 2023, and an award ceiling listed as $1,000,000. The opportunity is described as expecting a single award, consistent with the single-source intent. Eligibility language in the provided text emphasizes restrictions on non-U.S. entities: non-domestic (non-U.S.) institutions are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible. At the same time, the notice indicates that foreign components, as NIH defines them in its Grants Policy Statement, are allowed, which typically refers to discrete project elements performed outside the U.S. under a U.S. applicant organization, subject to NIH approval and specific policy requirements. The summary also includes an “Eligible Applicants: Small businesses” field in the extracted data, but the narrative portion clearly states the intent to issue the award to a specific university as a single-source continuation. As a result, this opportunity is best understood as a continuation mechanism to maintain an existing national research resource rather than an open competition seeking new entrants.

Overall, this funding opportunity is about sustaining the operational and scientific coordinating infrastructure that enables CureGN to keep producing consistent, high-value longitudinal data and biospecimen resources across multiple clinical centers. By continuing the DCC under a cooperative agreement, NIDDK is prioritizing stability in governance, data integrity, analytic capacity, and biosample coordination, all of which are essential for a long-running observational cohort study aimed at improving outcomes for people with glomerular diseases.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Single Source for the Continuation of Cure Glomerulonephropathy (CureGN) Data Coordinating Center (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2023-07-13.
• Applicants must submit their applications by 2023-10-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• Eligible applicants include: Small businesses.

Apply for RFA DK 22 513

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: